[HTML][HTML] Diagnostic properties of three SARS-CoV-2 antibody tests

S Basgalupp, G Dos Santos, M Bessel, L Garcia… - Diagnostics, 2021 - mdpi.com
S Basgalupp, G Dos Santos, M Bessel, L Garcia, AC de Moura, AC Rocha, E Brito
Diagnostics, 2021mdpi.com
Serological assays emerged as complementary tools to RT-PCR in the diagnosis of SARS-
CoV-2 as well as being needed for epidemiological studies. This study aimed to assess the
performance of a rapid test (RT) compared to that of serological tests using finger prick blood
samples. A total of 183 samples were evaluated, 88 of which were collected from individuals
with negative RT-PCR and 95 from positive RT-PCR individuals. The diagnostic
performance of RT (WONDFO®) and LUMIT (PROMEGA®) were compared to that of ELISA …
Serological assays emerged as complementary tools to RT-PCR in the diagnosis of SARS-CoV-2 as well as being needed for epidemiological studies. This study aimed to assess the performance of a rapid test (RT) compared to that of serological tests using finger prick blood samples. A total of 183 samples were evaluated, 88 of which were collected from individuals with negative RT-PCR and 95 from positive RT-PCR individuals. The diagnostic performance of RT (WONDFO®) and LUMIT (PROMEGA®) were compared to that of ELISA (EUROIMMUN®) for detecting antibodies against SARS-CoV-2 according to time from symptoms onset. The IgG antibody tests were detected in 77.4% (LUMIT), 77.9% (RT), and 80.0% (ELISA) of individuals. The detection of antibodies against SARS-CoV-2 increases in accordance with increasing time from symptoms onset. Considering only time from symptoms onset >21 days, the positivity rate ranged from 81.8 to 97.0% between the three tests. The RT and LUMIT showed high agreement with ELISA (agreement = 91.5%, k = 0.83, and agreement = 96.3%, k = 0.9, respectively) in individuals who had symptoms 15 to 21 days before sample collection. Compared to that of the ELISA assay, our results show sensitivity ranged from 95% to 100% for IgG antibody detection in individuals with symptoms onset between 15 and 21 days before sample collection. The specificity was 100% in individuals with symptoms onset >15 days before serological tests. This study shows good performance and high level of agreement of three immunoassays for the detection of SARS-CoV-2 antibodies.
MDPI